For Parents and Students: Minor Donor Permit and Information About Donating Blood
|
|
- Kristian Daniels
- 6 years ago
- Views:
Transcription
1 DIN NUMBER 102 Chestnut Ridge Road, Montvale NJ DID For Parents and Students: Minor Donor Permit and Information About Donating Blood Every day people like you need blood: students, teachers, family, and friends! And when blood is needed, blood must be there. The only source is generous volunteers like you! COMMON QUESTIONS ABOUT BLOOD DONATION Q: Is blood donation safe? Does it hurt? A: Donating blood is safe. All materials are used once, and then discarded. You cannot get any infectious disease by donating blood. Most people feel fine after they give. The actual needle stick (venipuncture) hurts no more than a pinch. Q: How long will it take? A: The entire process takes about 60 minutes, including the interview before and refreshment time after donation; automated donations take longer. Q: How much can I give? A: Every donor is evaluated individually with safety in mind! When you donate whole blood, one unit, about a pint is collected. Depending on your gender, height, and weight, you can give up to 2 units in an automated blood collection. For example, one donor may be able to donate two units of Red Blood Cells (RBC); another may donate a combination of Red Cells and Plasma, or just Plasma. For your safety, you must stay in the refreshment area at least 15 minutes following the donation. BLOOD DONOR QUALIFICATIONS In general, volunteer blood donors must be 16 or older and in good health. Blood Donation: The Process Whole Blood Donation Blood is collected from an arm vein into a bag specially designed to store blood. Typically, each unit is separated into multiple components, usually RBCs and Plasma. Whole blood donation is the most common way to donate blood. We also use special machines for automated blood collection. Automated Blood Collection Methods With automated equipment, the blood center can collect the exact components that patients need. Blood is collected from an arm vein and passed through an apheresis instrument that separates the blood into its components. During donation, a small amount of anticoagulant (citrate) is added to the blood to prevent clotting. After the targeted component(s) is/are collected, the remainder of the blood is returned to the donor. The donor may receive saline solution to help replace fluid lost during the collection. The body naturally replaces the donated components: plasma within several hours, platelets within 24 hours, and red cells in about 56 days (112 days for 2-unit Red Blood Cell donation). The number of white blood cells lost is small. Some Potential Side Effects Serious complications are rare. However, as in any medical procedure, there are certain risks. Potential side effects of both whole blood and automated blood collection include fainting, dizziness, nausea, vomiting, bruising or redness in the area of the venipuncture, and iron deficiency in individuals making 3 or more donation a year. More serious reactions may include seizures and, rarely, nerve injury in the area of the venipuncture. While a small proportion of blood donors have adverse reactions (overall reaction rate of 1.43%), donors aged 16 to 22 do experience a higher prevalence of reactions (about 5%). To reduce the likelihood of a reaction, the blood center evaluates eligibility for younger donors based on weight and height to determine blood volume. The chart above indicates whether your blood volume is sufficient for you to donate. Please review it carefully. Other Rev 12/2017 DC 41-0F1
2 possible complications include fatigue, decreased exercise tolerance for 3-5 days and, very rarely, allergic reaction, shortness of breath, chest pain, and decreased blood pressure. In addition, during automated blood collections some common side effects that are easily resolved are due to the anticoagulant and include numbness and tingling sensations, muscle cramping, and chilliness. Less common complications include hemolysis and air embolism. If you have any questions, please contact the blood center. STUDENTS: Take these steps on the day of donation for a good blood donation experience. If you are 16 or 17, bring this signed Minor Donor Permit when you donate. The signature block is below. BRING ID containing name and one of the following: birth date, blood center donor number, or photo. You must pass the physical and health history examination given prior to donation. If you have any questions regarding your eligibility, please check with your Blood Drive Coordinator or the blood center. Eat a healthy meal before donating, even if you do not normally eat three meals a day. Drink 16 ounces of fluid minutes before donating (soda, coffee, and tea don t count!). PARENTS/GUARDIANS: Help your student have a good blood donation experience. The Day Before Donation: Make sure your student eats a salty snack, like chips or pretzels, and has a meal that is higher in sodium, such as fast food, canned soup, pizza, etc. Physicians recommend this because donors lose about a gram of sodium during donation. Replacing some of that sodium ahead of time makes donors thirsty. Being well-hydrated helps donors maintain blood volume and can prevent dizziness or fainting. The Day of Donation: Make sure your student has a light meal before donating, and encourage your student to carefully follow our directions. Our staff are specially trained to respond to donor reactions. We will: Give your student reading material and instructions on how to have a safe, comfortable blood donation. Teach your student muscle tensing exercises to use during and after donation. Provide a sports drink or another beverage and a salty snack. Tell your student to spend at least 15 minutes in our refreshment area. Our blood center participates in research to improve blood safety. We may use your donor history information and a sample of your blood, in a confidential manner, for blood safety research, as described in the accompanying research information document(s). We are required to get parental consent for both 16- and 17-year old donors for this research. A sample from each blood donation will be tested for HIV (AIDS), HTLV, hepatitis, syphilis, and other infectious agents as required by regulations. These tests are performed to protect the patients who receive blood. Positive test results will be disclosed as authorized by law, and the donor will be notified. In some cases, blood center staff may need to discuss test results with the donor and or parents. Please be sure that you and your student have read the information provided. Your student must bring this signed Minor Donor Permit form in order to donate. I give my permission for my student to donate and for that donation to be tested as explained above. Parent/Guardian: Please complete all of the following using BLACK or BLUE INK. Student s Name: (Print) Parent/Guardian Name: (Print) (Signature) Date of Approval: (Month/Day/Year) Phone # where Parent/Guardian can be reached: Rev 12/2017 DC 41-0F1
3 Zika Virus Research Information Sponsor / Study Title: Hologic, Inc. / Pre-pivotal Procleix Zika Virus Assay Testing of Donations From Donors of Whole Blood and Blood Components Protocol Number: B10383-ZIKVPS-CSP-01 Principal Investigator: Philip Williams, PhD Telephone: Donor Counseling Service Additional Contacts: Ralph Vasallo, MD Please read this form carefully. Take time to ask the donor center staff as many questions about the use of your blood for research studies as you would like. The donor center staff can explain words or information that you do not understand. Reading this form and talking to the donor center staff may help you decide whether to donate or not. You are being asked to participate in a research study to evaluate a new test for detection of a mosquito-borne agent known as Zika virus. Zika is a virus that rarely causes paralytic nervous system damage, but in pregnancy, can cause loss of the baby or serious birth defects. Most people do not get sick after infection. Only one in five people will have fever, rash, joint pain, and conjunctivitis (red eyes) lasting a few days to a week. Zika is usually transmitted by the bite of an infected mosquito. It can also be transmitted by sex with an infected person, from a pregnant mother to her baby and by blood transfusion. This donor center is doing a research study to understand the effectiveness of new tests to detect Zika virus in donated blood and prevent patient exposure. Some of this research is conducted with other institutions, such as blood bank organizations, academic centers and biomedical companies. Any remainder of your donation may be stored up to 3 years after the completion of the study and used for further research related to the Zika virus. Samples linked to your identifying information will be tested for ZIKA virus. If your test results suggest that you may be infected, this donation center will attempt to contact you to notify you and explain the significance of the results. The donation center will discuss the potential risk for sexual transmission of Zika Virus, and potential harm to the fetus during pregnancy. You will be notified in person, by phone, or by letter. If your test results suggest that you may be infected, you should discuss these results with your primary care physician. You may also visit the Centers for Disease Control and Prevention (CDC) website at for additional information regarding Zika virus. If the results suggest that you may have a Zika virus infection, you will be invited to participate in voluntary follow-up studies involving additional blood samples. Should you choose to participate, additional informed consent process will be required. Your participation in this research study is entirely voluntary. You will not be paid for your participation in this study. Your participation will not require any additional procedures or time beyond the normal donation process. The risk of having your donation tested with the study test is not any greater than having your donation tested for other infectious diseases, although a positive result may alarm you. There is a very low chance that your blood sample may give a false positive result. If the test is positive, the blood that you donate will not be used for transfusion. There will be no costs or payments to you for your participation in this study. Although you may not receive a direct benefit from this study, the results may allow for better test systems to become available to protect the blood supply. The results of all testing on your donation during this study are confidential, except when reportable by Rev 12/2017 Page 1 of 2 DC 1-0e
4 Zika Virus Research Information law to public health authorities, and to authorized blood center personnel, the U.S. Food and Drug Administration (FDA), Hologic, Inc. and associated Zika studies. Your age, gender, general geographic location, and test results may be used to evaluate important information about Zika virus, but this information is combined with information about other donors and not identified with you. You may refuse to participate by notifying the blood collection staff that you will not be donating blood or blood components today. If you decline testing we will be unable to use your whole blood or red blood cells, however, we will inform you whether you may donate plasma or platelets. If you decide not to participate at this time, your decision will not change your future relationship with the blood center and there is no penalty to you. If you decide not to participate after your donation is taken, call the Principal Investigator at the number(s) above. An Independent Review Board (IRB) is a group of people who review research studies to protect the rights and welfare of research participants. If you have questions or complaints about your rights as a study participant contact the Chesapeake IRB: By mail: Study Subject Adviser Chesapeake IRB 6940 Columbia Gateway Drive, Suite 110 Columbia, MD or call toll free: or by adviser@chesapeakeirb.com Please reference the following number when contacting the Study Subject Adviser: Pro If you have scientific questions or questions about your participation in these studies, you may contact our Donor Counseling Service at between the hours of 6:30am to 5:30pm MST. By signing your Blood Donation Record, you are giving consent to allow us to use a portion of your blood donation and associated information for research purposes related to Zika virus. Community Blood Services ( Rev 12/2017 Page 2 of 2 DC 1-0e
5 # Use of Donor Information and Blood Samples in Research This blood center performs research to help provide a safe and effective blood supply. Research studies are conducted to improve blood safety and contribute to advancing biomedical knowledge. Some research is conducted with other institutions, such as blood bank organizations, academic centers and biomedical companies. Your participation in research studies is entirely voluntary. What will happen if I agree to allow my blood to be used in research studies? All research studies are evaluated and reviewed periodically by an independent committee that considers your rights as a research participant. Formal research studies are included in the clinical trial registry maintained by the National Institutes of Health for public access ( Your participation will not require any additional procedures or time beyond the normal donation process. There will be no payments to you for your participation. How might my blood or information be used in research? A portion of your blood sample or information collected at the time of donation may be used to make research studies possible. Some examples of the types of research are: New methods for testing for infectious diseases. Studies relating to testing, storing, collecting, and processing blood. Studies of ways to recruit blood donors and evaluate donor eligibility. Will my results and information be kept confidential if they are used for research purposes? Samples used by researchers will have your identifying information removed. Only authorized blood center personnel can link samples to your identifying information. Strict procedures are observed at all blood collection facilities to maintain your confidentiality. Identifying information will not be revealed to anyone unless required by law. How might my sample be tested and will I be informed of results? Samples linked to your identifying information may be used for infectious disease testing to provide safe blood. You will be notified in person, by phone, or by letter, about any test results that may impact your health. What will happen if my blood sample or information is stored for future research on blood safety? If your sample is stored for research purposes, only authorized blood center personnel can link it to your identifying information. Your identified sample and information will not be used for research unrelated to blood safety or advancing biomedical knowledge. What benefit will I receive for participating in a research study? No benefit will be provided directly to you. However, use of blood donor data and samples for research provides for increased blood safety and understanding of health and disease. Does my participation create any risk for me? The risk of participating in these research studies is very small. There is a very low chance that your blood sample may give a result that means the blood that you donate will not be used for transfusion and there is a possibility that you may not be able to donate again. If this happens, additional testing may be available to help clarify the results and we will discuss these results and your eligibility to donate with you. What else may happen due to my participation? If your test results are positive or unexpected, you may be asked to participate in a follow-up study. Participation is voluntary and of no cost to you. Follow-up studies frequently involve completing a short questionnaire and providing additional samples for further testing. Information about follow-up studies will be provided to you before requesting your participation. Should you choose to participate, an additional informed consent process will be required. What are my rights? You may refuse to participate by notifying blood collection staff that you do not want your donation to be used for research and that you will not be donating blood or blood components today. If you decide to withdraw after leaving the donation site, contact the blood center at. However, test information collected before your withdrawal request may still be used after you are removed from the study. If you decide that you do not want your donation to be used for research, you will not be able to donate today. It is very important to include all blood donors and their donations in possible research studies to continue to provide a safe and effective blood supply. If you decide not to participate at this time, your decision will not change your future relationship with the blood center. Whom should I contact if I have more questions? For more information about research uses of your blood or information, call at. If you have questions about your rights as a research participant, call the Western Institutional Review Board administrator at (360) ). By signing your, you are giving consent to allow us to use a portion of your blood donation and information for research purposes. CTS FORM (Rev. 2) You may keep this information sheet for future reference.
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A Pilot Study for Collection of Anti-Zika Immune Plasma
A Pilot Study for Collection of Anti-Zika Immune Plasma CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts for this study at the Hospital of the University
UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM
UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT AND HIPAA AUTHORIZATION FORM Protocol Title: Principal Investigator: 24 hr. Emergency Contact: Evaluating the HIV-1 Reservoir: BEAT HIV Delaney
INFORMATION AND CONSENT FORM For Adults Aged 18 and Older Additional Facility Sites
INFORMATION AND CONSENT FORM Program Title: Expanded Access IND Program to Provide Stamaril Vaccine to Persons in the United States for Vaccination Against Yellow Fever Program #: Sponsor: Sanofi Pasteur
The Johns Hopkins Bloomberg School of Public Health
The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:
IRB Approval From: 3/8/2010 To: 10/28/2010
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 (Version 3.0, 16 FEB 2010) IRB Approval From:
Making Your Blood Donation Safe
BLOOD DONOR EDUCATIONAL MATERIALS Making Your Blood Donation Safe Pete Lawson Burned in a wildfire, LifeStream blood donations saved his life. WWW.LSTREAM.ORG NEW! Important Information on Iron! Recent
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Study Title: Assessment of Biochemical Pathways and Biomarker Discovery in Autism Spectrum Disorder This is a research
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
White Blood Cell Collection by Leukapheresis in HIV-infected Individuals On Chemotherapy and Controls Not on Chemotherapy: A Study of HIV Reservoir Eradication CONSENT TO PARTICIPATE IN A RESEARCH STUDY
Subject Name: Sponsor Consent Tmplt Date: Version 2 (17-Jul-2014) Unit Number:
SCREENING CONSENT TO DETERMINE STUDY ELIGIBILITY AND OPTIONAL RESEARCH AUTHORIZATION TO DONATE ARCHIVED TISSUE SAMPLES FOR MOLECULAR CHARACTERIZATION OF TUMOR YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
Gilead Sciences, Inc. GS-US-337-0115, 25-NOV-2013 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects
Make a difference! Your guide to saving lives through blood donation
Make a difference! Your guide to saving lives through blood donation You have the power to change lives Every two seconds someone needs blood. Accidents happen 24/7, putting family, friends, and neighbors
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol No. VRX496-USA-11-001-LTFU: Long-term Follow-up
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
IRC 002, Version 5.0, 20 AUG 2012: A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-influenza A Immune Plasma for the Treatment of Influenza
IRB Approved: 09-Jan-2015 To: 08-Jan-2016
Developing Assays to Evaluate Immunologic Response to HIV and HIV Vaccines CONSENT FORM/HIPAA AUTHORIZATION FOR VENIPUNCTURE Investigators: Pablo Tebas, MD Phone Number: (215) 349-8092 Study Staff: Joseph
Donor Registration and Consent for HLA Typing
Place NMDP Bar Code label here Jackie (left), donated to save the life of Paizley (right) Randy (left), donated to save the life of Luke (right) Tobias (left), donated to save the life of Betsy (right)
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Epileptic Encephalopathies: Clinical and Genetic Predictors of Outcomes and Therapeutic Insights This is a research study.
We are inviting you to participate in a research study/project that has two components.
Dear TEACCH Client: One of the missions of the TEACCH Autism Program is to support research on the treatment and cause of autism and related disorders. Therefore, we are enclosing information on research
University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION
University of Pennsylvania RESEARCH Subject Informed Consent Form AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: Evaluating the impact of cocaine use and HIV infection in arterial wall inflammation
PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1
The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment
IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014
Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: The goal of Assisted Reproductive Technology (ART) is to help infertile couples to become pregnant. During treatment, some cellular
VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION
VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION Study Title: Cytokine Production and Lymphoproliferation With and Without Co-inhibitory Signaling Blockade: An Assessment of Functional
CONSENT TO PARTICIPATE IN A RESEARCH STUDY. Why are you being invited to take part in a research study?
HRP-502 (6/1/2016) LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER in Shreveport Institutional Review Board (IRB) for the Protection of Human Research Subjects Remove all instructional text and red color-coding
UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT FORM
UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT INFORMED CONSENT FORM Protocol Title: Principal Investigator: Emergency Contact: AN OPEN LABEL TRIAL OF MECASERMIN FOR HIV ASSOCIATED METABOLIC DISEASE Roy Kim
A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination
A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination Sponsor: University of Oxford EudraCT No.: 2014-000730-30 REC: South Central Oxford A REC
Language for Consent Forms
New York University University Committee on Activities Involving Human Subjects 665 Broadway, Suite 804, New York, NY 10012 VOICE: 212-998-4808 FAX: 212-995-4304 www.nyu.edu/ucaihs/ Language for Consent
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts
CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
CONSENT TO BE A RESEARCH PARTICIPANT Version of the Informed Consent DAIDS-ES 20730 Impact of CCR5 Blockade in CONSENT VERSION 3.0 /October 2, 2017 PROTOCOL VERSION 3.0 /October 2, 2017 [NOTE: Site specific
Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH
Northwestern University Department of Urology CONSENT FORM AND AUTHORIZATION FOR RESEARCH Project Title: Genetics of Prostate Cancer Principal Investigator or Faculty Advisor: William J. Catalona, M.D.
UNIVERSITY HOSPITALS CASE MEDICAL CENTER CONSENT FOR INVESTIGATIONAL STUDIES (v )
UNIVERSITY HOSPITALS CASE MEDICAL CENTER CONSENT FOR INVESTIGATIONAL STUDIES (v. 11.2012) Project Title: The Impact of Achilles Tightness on Lower Etremity Injuries in Adolescent Athletes Principal Investigator:
Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus
Page 1 of 8 Informed Consent for Participation in a Research Study Title of Research Study: Discovery and Validation of Biomarkers for Lichen Sclerosus Investigator Contact Information: Principal Investigator:
About this consent form. Why is this research study being done? Partners HealthCare System Research Consent Form
Protocol Title: Gene Sequence Variants in Fibroid Biology Principal Investigator: Cynthia C. Morton, Ph.D. Site Principal Investigator: Cynthia C. Morton, Ph.D. Description of About this consent form Please
Participant Information Leaflet
Participant Information Leaflet Research: Hand to nose transmission of Streptococcus pneumoniae in healthy participants: randomised control trial assessing the effect of hand Would you like to take part
HREC/17/RCHM/334 RCH HREC 37278A. ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank.
HREC Project Number: Research Project Title: Principal Researchers: HREC/17/RCHM/334 RCH HREC 37278A ANZ CLARITY Establishment of a National Juvenile Idiopathic Arthritis Biobank. Associate Professor Justine
Answers. To Your. Questions
Blood Transfusions Answers To Your Questions Answers to Your Questions This brochure is intended for people who may need a blood or blood product transfusion and for those who regularly receive transfusions.
Prof A Pourazar Immunohematologist
Prof A Pourazar Immunohematologist What is plasma? Plasma is part of blood. It is the liquid that supports the circulation of red blood cells, white blood cells and platelets. Plasma is mainly water and
We are inviting you to participate in a research study/project that has two components.
Dear TEACCH Client: One of the missions of the TEACCH Autism Program is to support research on the treatment and cause of autism and related disorders. Therefore, we are enclosing information on research
Patient Information Sheet
Research Trial of Treatments for Patients with Bony Metastatic Cancer of the Prostate. - TRAPEZE Patient Information Sheet Your doctor has explained to you that your prostate cancer is no longer responding
UNIVERSITY OF WASHINGTON MEDICAL CENTER Men s Health Center and Male Fertility Laboratory Sperm & Testis Cryopreservation Program Patient NAME and ID
UNIVERSITY OF WASHINGTON MEDICAL CENTER Men s Health Center and Male Fertility Laboratory Sperm & Testis Cryopreservation Program Patient NAME and ID CONSENT FOR MINOR s SPERM OR TESTIS CRYOPRESERVATION
HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT FOR OPTIONAL PROCEDURES AND SAMPLES COLLECTION AFTER WEEK 48
CONSENT FOR OPTIONAL PROCEDURES AND SAMPLES COLLECTION AFTER WEEK 48 Protocol Title: A5354 Version 1.0, dated 4/19/16, Letter of Amendment #1, 12/13/16, Letter of Amendment #2, 11/7/17 Effect of Antiretroviral
Autologous plasma eye drops. Patient information
Autologous plasma eye drops Patient information Autologous plasma eye drops are made from the patient s own blood and are used to help treat their corneal surface defects and diseases. This leaflet gives
Douglas V. Faller, Ph.D., M.D., Susan P. Perrine M.D.
ARGININE BUTYRATE + GANCICLOVIR IN EBV (+) MALIGNANCY A PHASE ONE TRIAL OF BUTYRATE IN COMBINATION WITH GANCICLOVIR IN EBV-INDUCED MALIGNANCIES AND LYMPHOPROLIFERATIVE DISEASE Principal Investigators:
If you want to learn more about this study, you are welcome to read the full consent form and the patient handbook.
What is this research study about? You are being asked to be in this study because you are at increased risk of getting type 1 diabetes. You have already been assigned to a treatment group and have completed
Understanding your risk of blood clots from hospital to home and how Bevyxxa may help
Understanding your risk of blood clots from hospital to home and how Bevyxxa may help People who take Bevyxxa and have medicine injected into their spinal and epidural area, or have a spinal puncture,
Informed Consent And Authorization To Disclose Health Information
Gynecologic Cancer Research Foundation Page 1 of 11 Informed Consent And Authorization To Disclose Health Information Sponsor / Study Title: Principal Investigator: (Study Doctor) Gynecologic Cancer Research
Guidance for Industry
Guidance for Industry Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs Additional copies of this guidance are available from the Office
Vanderbilt University Institutional Review Board Informed Consent Document for Research. Name of participant: Age:
This informed consent applies to: Adults Name of participant: Age: The following is given to you to tell you about this research study. Please read this form with care and ask any questions you may have
BLOOD TRANSFUSIONS. Answers. To Your. Questions
BLOOD TRANSFUSIONS Answers To Your Questions Answers to Your Questions This brochure is intended for people who may need a blood or blood product transfusion and for those who regularly receive transfusions.
Information for patients with Sickle Cell Disease who may need a blood transfusion. Patient information
Information for patients with Sickle Cell Disease who may need a blood transfusion Patient information This information leaflet answers some of the questions you may have about having a blood transfusion
CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY
CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY INVESTIGATOR S NAME: PAMELA S. HINTON PH.D. PROJECT # 1095877 DATE OF PROJECT APPROVAL: SEPTEMBER 12, 2007 STUDY TITLE: EFFICACY OF PLYOMETRICS TO INCREASE
NCI Community Oncology Research Program Kansas City (NCORP-KC)
NCI Community Oncology Research Program Kansas City (NCORP-KC) Consent Form Study Title for Study Participants: Comparing Two Dose Levels of Bupropion Versus Placebo for Sexual Desire Official Study Title
IMPORTANT HEALTH INFORMATION
IMPORTANT HEALTH INFORMATION SU-6523MI Page 1 of 8 Table of Contents Page What is an HIV test?..........................................1 Will the HIV test tell me if I have AIDS?............................1
BLOOD TRANSFUSIONS. Answers. To Your. Questions
BLOOD TRANSFUSIONS Answers To Your Questions Answers to Your Questions This brochure is intended for people who may need a blood or blood product transfusion and for those who regularly receive transfusions.
THE KRONGRAD INSTITUTE Sep 25, 2008 WIRB RESEARCH SUBJECT INFORMATION AND CONSENT FORM
RESEARCH SUBJECT INFORMATION AND CONSENT FORM TITLE: LAPAROSCOPIC PROSTATECTOMY FOR CHRONIC PROSTATITISA Phase II Non-Randomized Clinical Trial PROTOCOL NO.: 1 Protocol #20081635 SPONSOR: INVESTIGATOR:
Northwestern University. Consent Form and HIPAA Authorization for Research
Northwestern University Consent Form and HIPAA Authorization for Research PROTOCOL TITLE: Yoga Versus Resistance Training in Parkinson s Disease: A Randomized, Controlled Pilot Study of Feasibility & Efficacy
INFORMATION SHEET FOR THE DEPARTMENT OF PAIN AND PALLIATIVE CARE
INFORMATION SHEET FOR THE DEPARTMENT OF PAIN AND PALLIATIVE CARE Please review the following instructions as it contains important information regarding the management of your pain. Once reviewed, our
A study of Standard and New Antiepileptic Drugs SANAD-II
The SANAD II project is funded by the NIHR Health Technology Assessment Programme. Hospital Logo Address NIHR code A study of Standard and New Antiepileptic Drugs SANAD-II ADULT INFORMATION SHEET www.sanad2.org.uk
Myocardial perfusion (heart) scan - Nuclear Medicine
University Teaching Trust Myocardial perfusion (heart) scan - Nuclear Medicine Turnberg Building Nuclear Medicine All Rights Reserved 2017. Document for issue as handout. Please read this booklet carefully
NCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG Informed Consent Template for Cancer Treatment Trials (English Language)
Page 1 of 15 NCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG 1112 Informed Consent Template for Cancer Treatment Trials (English Language) RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS
About this consent form
Protocol Title: Development of the smoking cessation app Smiling instead of Smoking Principal Investigator: Bettina B. Hoeppner, Ph.D. Site Principal Investigator: n/a Description of Subject Population:
Commonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO BE IN RESEARCH CC#:125519: Radiologically Guided Biopsies Of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms Of Resistance
National Emphysema Treatment Trial (NETT) Consent for Randomization to Treatment
National Emphysema Treatment Trial (NETT) Consent for Randomization to Treatment Instructions: This consent statement is to be signed and dated by the patient in the presence of a certified study staff
Frequently Asked Questions From Colleagues or Members, Tips and Pointers
Frequently Asked Questions From Colleagues or Members, Tips and Pointers When you approach your colleagues or members about making an appointment to donate blood, some may not be eager to sign up to start
INFORMATION BROCHURE - ALLOCATE
INFORMATION BROCHURE - ALLOCATE AustraLian Ovarian Cancer Assortment Trial Principal Investigator: Prof Michael Quinn, Royal Women s Hospital This Participant Information Sheet and Consent Form is 7 pages
Study Plan: Screening
Phase 1 with Sporozoite Challenge Open-Label Dose-Escalation Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium falciparum Malaria Protein (FMP012), an E coli-expressed
PATIENT AUTHORIZATION AND NOTICE OF RELEASE OF INFORMATION (PAN)
XOLAIR Access Solutions is a free program for you from Genentech. We work to help you pay for your XOLAIR (omalizumab) for subcutaneous use. We can help in many different ways. We assist people who have
Blood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.
Blood Transfusion Introduction Blood transfusions can save lives. Every second, someone in the world needs a blood transfusion. Blood transfusions can replace the blood lost from a serious injury or surgery.
INFORMATION AND CONSENT FORM
INFORMATION AND CONSENT FORM A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY OF SELF- ADMINISTERED AND NURSE-ADMINISTERED INTRADERMAL INFLUENZA VACCINE Investigators Dr. Shelly McNeil Queen
Juventas SHARING LIFE CONSENT FOR PLASMA INFUSION
Juventas SHARING LIFE Print Name Date of Birth CONSENT FOR PLASMA INFUSION To the Patient or Guardian of the Patient: The purpose of this document is to provide written information as of (month and day),
PART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr THALOMID Thalidomide Capsules House Standard This leaflet is part III of a three-part "Product Monograph" published when THALOMID (thalidomide ) was approved for sale
GARDEN STATE SLEEP CENTER REGISTRATION FORM PATIENT INFORMATION:
GARDEN STATE SLEEP CENTER REGISTRATION FORM (Please Print) Today s Date: Primary Care Physician: PATIENT INFORMATION: Last Name: First: Middle: Mr. Miss Dr. Mrs. Ms. Marital Status (Please check one) Single
Johns Hopkins Hospital Comprehensive Transplant Center Informed Consent Form for Thoracic Organ Recipient Evaluation
Johns Hopkins Hospital Comprehensive Transplant Center Informed Consent Form for Thoracic Organ Recipient Evaluation The decision to undergo transplantation can be extremely difficult and often confusing.
Name of Recipient: Recipient s DOB (if known) Relationship to Recipient: (Example: mother, father, sister, brother, friend, etc)
The Christ Hospital Health Network DONOR REGISTRATION INFORMATION Phone: 513-585-2493 Fax: 513-585-0433 (Please be advised donor information is needed ONLY to register donor in the Christ Hospital system.
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
IRC 004, Version 5, July 31, 2013 A Randomized Double-Blind Study Comparing Oseltamivir versus Placebo for the Treatment of Influenza in Low Risk Adults CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH
INFORMATION AND ASSENT FORM. Ages 7-17
INFORMATION AND ASSENT FORM Program Name: Program Number: Sponsor: Expanded Access IND Program to Provide Stamaril Vaccine to Persons in the United States for Vaccination Against Yellow Fever Sanofi Pasteur
Allogeneic donor selection and blood collection. by Mohammed Abu-basha
Allogeneic donor selection and blood collection 1 An allogeneic (also called homologous) donation (allo- from the Greek meaning "other") is when a donor gives blood for storage at a blood bank for transfusion
Pro Active Physical Therapy & Sports Medicine
Pro Active Physical Therapy & Sports Medicine Consent and Statement of Financial Responsibility 1. CONSENT FOR TREATMENT: I consent to and authorize my physical therapist, occupational therapist and other
Town of Wolfeboro New Hampshire Health Notice Wolfeboro Public Health Officer Information Sheet Zika Virus
Aedes Zika Virus Information Sheet Town of Wolfeboro New Hampshire Health Notice Wolfeboro Public Health Officer Information Sheet Zika Virus The Zika Virus is a mosquito borne illness spread by the Aedes
BLOOD DONATION Northern Ireland Blood Tranfusion Service
FREQUENTLY ASKED QUESTIONS BLOOD DONATION Northern Ireland Blood Tranfusion Service Why do we need donated blood? Everyone knows blood is literally a lifesaver for those who have been in an accident or
A Patient s Guide to Blood Components and Products
2014 A Patient s Guide to Blood Components and Products Contents What is a blood transfusion?... 1 Informed consent... 1 Frequently asked questions about blood transfusions... 2 What can I expect during
Integrative Consult Patient Background Form
Let Us Know More - So We Can Help Thank you for choosing to schedule an integrative medicine consultation with UC Health. To help us meet your needs during your visit, please take some time to sit in a
What You Need to Know about a Heart Transplant
Page 1 of 8 What You Need to Know about a Heart Transplant This information will help you understand the risks, benefits, and possible complications involved in a heart transplant. Please read it carefully.
Bloodborne Pathogens. Post-Exposure Incident Packet. An Informational Guide
Bloodborne Pathogens Post-Exposure Incident Packet An Informational Guide Faribault Public Schools Bloodborne Pathogens Post-Exposure Incident Packet This packet has been developed as an informational
Adult Patient Information and Consent Form
The ROAM Trial Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial
USER INSTRUCTIONS HPC, Cord Blood Donor History Questionnaire. Table of Contents
Page 1 of 9 USER INSTRUCTIONS HPC, Cord Blood Donor History Questionnaire Table of Contents Purpose Introduction Capture Questions Methods of Administration DHQ Materials Structure and Content Reformatting
You are the parent or guardian granting permission for a child in this study.
Please check one of the following: You are an adult participant in this study. You are the parent or guardian granting permission for a child in this study. Print child s name here: The following information
Daunorubicin daw-no-roo-bih-sin
Patient Education daw-no-roo-bih-sin This medicine, like all medicines used to treat cancer, is very strong. Make sure you understand why you are getting it and what the risks and benefits of treatment
Suspected CANcer (SCAN) Pathway Information for patients
Suspected CANcer (SCAN) Pathway Information for patients page 2 Your GP has advised you may benefit from investigation via the SCAN pathway. The SCAN pathway is part of a national programme called ACE
Informed Consent Flipchart. Version 1.0, 30 Jan 2018
Informed Consent Flipchart Version 1.0, 30 Jan 2018 Knowledge is Power Did you know? Across the world, young women are at high risk of getting HIV. In Africa, more than half of people living with HIV are
Iowa Methodist Medical Center Transplant Center. Informed Consent for Kidney Transplant Recipient
Iowa Methodist Transplant Center Iowa Methodist Medical Center Transplant Center 1215 Pleasant Street, Suite 506 Des Moines, IA 50309 515-241-4044 Phone 515-241-4100 Fax Iowa Methodist Medical Center Transplant
Zika Virus Identifying an Emerging Threat. Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services
Zika Virus Identifying an Emerging Threat Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services What is Zika Virus? Zika virus is a vector-borne disease
Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016
Dear Health Care Provider: Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay September 7, 2016 The U.S. Food and Drug Administration (FDA) has issued an Emergency
MEDICATION GUIDE. Epogen (Ee-po-jen) (epoetin alfa)
MEDICATION GUIDE Epogen (Ee-po-jen) (epoetin alfa) Read this Medication Guide before you start Epogen, each time you refill your prescription, and if you are told by your healthcare provider that there
Jumpstart, Fitness Assessment, & Body Composition
Jumpstart, Fitness Assessment, & Body Composition Waiver, Release and Hold Harmless Agreement In consideration of permission granted by Purdue University allowing me to participate in Personal Training
HEALTH SCREENING QUESTIONNAIRE CT Work-up. Donor ID EdgeCell #:
HEALTH SCREENING QUESTIONNAIRE CT Work-up Héma-Québec Registre des Donneurs de Cellules Souches 4045 Côte-vertu, St-Laurent, QC, Canada, H4R 2W7 Tél : + 514-832-1031 Fax : + 514-832-0266 www.hema-quebec.qc.ca
INFORMATION SHEET. Assessment of health, fitness & performance
INFORMATION SHEET Assessment of health, fitness & performance You are invited to take part in physiological/assessment tests as part of educational/ consultancy activities conducted by the Sport and Exercise
Consent and Authorization Document
Kalani Raphael, MD Page 1 of 14 Consent and Authorization Document BACKGROUND You are being asked to participate in this research study because you have chronic kidney disease, also called CKD, a condition
INTRODUCTION --- COLLEGE IMMUNIZATIONS
INTRODUCTION --- COLLEGE IMMUNIZATIONS The Ohio Revised Coded (ORC) Section 1713.55 states that beginning with the academic year that commences on or after July 1, 2005, an institution of higher education
PARTICIPANT INFORMATION SHEET. Clinical trial to evaluate a new Hepatitis B vaccine (CONSTANT study)
Oxford Vaccine Group University of Oxford Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE Telephone: 01865 611400 info@ovg.ox.ac.uk www.ovg.ox.ac.uk